翻訳と辞書 |
Omapatrilat
Omapatrilat (INN) is a novel antihypertensive agent that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme. NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling. This drug from Bristol-Myers Squibb was not approved by the U.S. Food and Drug Administration due to angioedema safety concerns.〔Joshi Venugopal. (2003) Pharmacological modulation of the natriuretic peptide system. Expert Opinion on Therapeutic Patents 13:9, 1389〕 Omapatrilat angioedema was attributed to its dual mechanism of action, inhibiting both angiotensin converting enzyme (ACE), and neutral endopeptidase, both of these enzymes are responsible for the metabolism of bradykinin which causes vasodilation, angioedema, and airway obstruction. ==Clinical uses== The drug was promoted for possible uses in congestive heart failure.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Omapatrilat」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|